Navigation

Costing tools

Costing tools are normally provided for each technology appraisal, quality standard, medical technology, diagnostic technology, clinical guideline and public health guidance. Costing tools are not provided for interventional procedures.

Types of costing tool

NICE provides five types of costing tool:

  • national cost reports summarise the national estimate cost and discuss the assumptions made when estimating the financial impact of implementing the guidance. For technology appraisals, the report is incorporated into the costing template.
  • costing templates support estimating the local cost of implementing guidance. and public health guidelines. These templates allow individual NHS organisations and local health economies to quickly assess the impact guidance will have on local budgets. A video tutorial explaining how to use the costing templates is available in Windows Media Player and Quick Time format.
  • business case. It presents the financial costs and benefits of implementing guidance.
  • cost impact and commissioning assessment for NICE quality standards
  • costing statements are used when cost impact is considered to be minimal to explain why the cost impact is not considered to be significant.
  • NICE support for commissioners and others using the quality standard

All guidance published since January 2005 has costing tools. Costing tools currently available are listed below.

Further information on the methodology for developing costing tools.

Results 41-60 of 511

Ref Title
TA264 Stroke (acute, ischaemic) - alteplase: costing template
TA263 Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer: costing statement
TA261 Venous thromboembolism (treatment and long term secondary prevention) - rivaroxaban: costing template
TA260 Migraine (chronic) - botulinum toxin type A: costing template
TA259 Prostate cancer (metastatic, castration resistant) - abiraterone (following cytoxic therapy): costing template
TA258 Lung cancer (non small cell, EGFR-TK mutation positive) - eroltinib (1st line): costing statement
TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): costing statement
TA256 Atrial fibrillation (stroke prevention) - rivaroxaban: costing template
TA255 Prostate cancer - cabazitaxel: costing statement
TA254 Multiple sclerosis (relapsing-remitting) - fingolimod: costing template
TA253 Hepatitis C (genotype 1) - boceprevir: costing template
TA252 Hepatitis C (genotype 1) - telaprevir: costing template
TA251 Leukaemia (chronic myeloid, first line) - dasatinib, nilotinib and standard-dose imatinib: costing statement
TA250 Breast cancer (advanced) - eribulin: costing statement
TA249 Atrial fibrillation - dabigatran etexilate: costing template
TA248 Diabetes (type 2) - exenatide (prolonged release): costing statement
TA247 Rheumatoid arthritis - tocilizumab (rapid review TA198): costing statement
TA246 Venom anaphylaxis - immunotherapy pharmalgen: costing statement
TA245 Venous thromboembolism - apixaban (hip and knee surgery): costing statement
TA244 Chronic obstructive pulmonary disease - roflumilast: costing statement

This page was last updated: 31 August 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.